Joint statement offers new recommendations for treating cardiovascular conditions
the ONA take:
A new scientific statement issued jointly by the American Heart Association, American College of Cardiology, and American Society of Hypertension addresses treatment goals for patients with high blood pressure who also have vascular diseases.
The statement acknowledges that a target blood pressure of less than 140/90 mm Hg is reasonable to reduce the risk of heart attacks and strokes in the general population, a lower target of less than 130/80 mm Hg may be appropriate for some patients with heart disease who have already experienced a stroke, heart attack, or mini-stroke (transient ischemic attack [TIA]).
Additional recommendations and contraindications include which antihypertensives to use in patients with various types of heart disease. The statement also recommends lowering blood pressure slowly in patients with coronary artery blockages.
Furthermore, clinicians should not strive to lower the diastolic number to less than 60 mm Hg, especially in patients older than 60 years.
These recommendations also reiterate the importance of modifying other risk factors, including abdominal obesity, abnormal cholesterol, diabetes, and smoking.
New statement addresses treatment goals for patients with high blood pressure who also have vascular diseases.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|